Claims for Patent: 9,629,852

Summary for Patent: 9,629,852

Title:	Ophthalmic composition comprising a prostaglandin
Abstract:	The present invention relates to a pharmaceutical composition suitable for ophthalmic use comprising one or more prostaglandin derivatives or salts, a stabilizing amount of polyethylene glycol hydroxystearate and pharmaceutically acceptable vehicle.
Inventor(s):	Khopade; Ajay Jaysingh (Baroda, IN), Halder; Arindam (Baroda, IN), Bhowmick; Subhas Balaram (Baroda, IN)
Assignee:	SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (Mumbai, IN)
Application Number:	12/601,429
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,629,852
Patent Claims:	1. A pharmaceutical composition suitable for ophthalmic use comprising 0.005% w/v latanoprost or a pharmaceutically acceptable salt therof, 0.15% w/v castor oil, 0.2 to 0.75% w/v of polyethylene glycol hydroxystearate, a co-solvent, a chelating agent, a preservative, and pharmaceutically acceptable vehicle, wherein the ratio of oil to polyethylene glycol hydroxystearate is less than 1.0, wherein the composition is in the form of a self-emulsifying micro-emulsion with average droplet size of about 100 nm or less and a zeta potential between -0.1 mV to -20 mV, wherein the composition does not comprise a cationic surfactant, and wherein the composition does not comprise a quaternary ammonium compound. 2. The pharmaceutical composition as claimed in claim 1 Wherein the emulsion has an average droplet size of less than 100 nanometers in diameter. 3. The pharmaceutical composition as claimed in claim 2, wherein the emulsion has a percent transmission greater than 70%. 4. The pharmaceutical composition as claimed in claim 2, wherein the emulsion has a percent transmission greater than 80%. 5. The pharmaceutical composition as claimed in claim 1 wherein the composition does not show any clinical sign of ocular irritation when tested in rabbits.